IRBNet #	PRINCIPAL INVESTIGATORS	PROTOCOL DESCRIPTION	SPONSORS	RESEARCH TEAM Contact
		CENTER OF GLOBAL HEALTH and TRANSLATIONAL SCIENCE / DEPARTMENT OF MEDICINE Division of Infectious Disease		
692535	Timothy Endy, MD	Phase 1, Open Label, Assessment of a Dengue -1- Virus-Live Virus Human Challenge (DENV-1-LVHC) Virus Strain	The Surgeon General/ Department of the Army	Michelle Klick, LPN, CCRP <b>315-464-5729</b>
790117	Timothy Endy, MD	Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-Exposure Prophylaxis. A Randomized, Open Label Trial in Healthy US Adults. Age 18-60 years	Department of Defense; Walter Reed Army Institute for Research	Shannon Atkins, CCRP <b>315-464-7681</b>
880000	Elizabeth Asiago- Reddy, MD	A Multicenter, Randomized, Double- blind, Placebo-controlled Trial, Followed by Single-Arm Treatment of PRO 140 in Combination with Optimized Background Therapy Treatment-Experienced HIV-1 Subjects	CytoDyn	Kelly Bartlett, CCRP <b>315-464-7687</b>
929182	Elizabeth Asiago- Reddy, MD	Multicenter Study to Assess the Clinical Safety & Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 wks in Virologically Suppressed Subjects with CCR5-tropic HIV-1 infection	CytoDyn	Kelly Bartlett, CCRP <b>315-464-7687</b>
929647	Kristopher Paolino, MD	Specimen Collection from Healthy Volunteers for In Vitro and Animal Research	Internal	Michelle Klick, LPN, CCRP <b>315-464-5729</b>
950161	Elizabeth Asiago- Reddy, MD	Effects of cART Long-term Exposure on Neuronal Function and Brain Microstructure in HIV Infected individuals ART Naïve starting cART	National Institute Mental Health	Kelly Bartlett, CCRP <b>315-464-7687</b>
1096921	Kristopher Paolino, MD	Evaluation of Rapid Diagnostic Device Based on Immunochromatographic Test Technology for the Identification of Causative Etiological Agents in Persons Exhibiting Signs and	InBios	Kate Caiello <b>315-464-7679</b>

1105397	Elizabeth Asiogo-	Symptoms of Febrile Illnesses- DENV Detect Rapid Test A Phase III, randomized,	GSK	Kelly Bartlett,
1105357	Reddy, MD	multicenter parallel-group, non- inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed		CCRP 315-464-7687
1102502	Kristopher Paolino, MD	Phase 2b, Multicenter, randomized DB, controlled to evaluate the efficacy & safety of IV VIS410 in addition to Oseltamivir(Tamiflu) compared w/ Oseltamivir alone in hospitalized adults w/ influenza A inf. requiring o2	Visterra, Inc.	Michelle Klick, LPN, CCRP <b>315-464-5729</b>
1158092	Albright, DO, PhD	Personalized Antiplatelet Secondary Stroke Prevention (PASSPoRT). A randomized, Phase II, Open Label, Trial Ischemic Stroke Survivors Age 18 years and older.	Dept of Neurology and UMU College of Medicine	Kelly Bartlett, CCRP <b>315-464-7687</b>